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ABSTRACT
Background: Chronic kidney disease (CKD) is increasingly recognized as a global public health problem. 
Cardiovascular disease (CVD) is a major cause of mortality in patients with mild-to-moderate CKD and 
end-stage renal disease. There is accumulating evidence that the increase in CVD burden is present in CKD 
patients prior to dialysis, due both to conventional risk factors and kidney-specific disease. Detection and 
initiation of treatment for CVD risk factors at early stages of CKD should be effective in reducing CVD events 
before as well as after the onset of kidney failure. Materials and Methods: The study sample consisted of a 
total of 112 subjects aged ≤12 years: 60 CKD patients and 52 healthy control individuals. All subjects were 
investigated for a group of CVD risk factors such as: Hypertension, diabetes, dyslipidemia, physical inactivity, 
body mass index (BMI), family history of CVD, hypoalbuminemia, albuminuria, anemia, Ca x P product, and 
inflammation in terms of C-reactive protein (CRP). Results: Patients (40 males and 20 females) were categorized 
into four CKD stages (2, 3, 4, and 5) where, Stage 4 had the highest frequency, followed by Stages 3, 5 and 
2. Evaluation of the patients indicated that they were shorter, had lower weight and had higher systolic and 
diastolic blood pressure as compared with control subjects. Frequency of physical inactivity among patients 
was two-fold higher than controls (50% vs. 25%). The patients showed significantly higher levels of cholesterol 
(163.6±39.8 vs. 141.8±24.2 mg/dL, P<0.0001), triglycerides (145.5±67.1 vs. 82.9±39.8 mg/dL, P<0.0001), 
low-density lipoprotein (92.6±31.9 vs. 72.5±19 mg/dL, P<0.0001) and albumin/creatinine ratio (1792±3183 vs. 
11.1±6.6 mg/g, P<0.0001). Moreover, the patients had lower levels of high-density lipoprotein (41.9±11.0 vs. 
52.7±11.7 mg/dL, P<0.0001), hemoglobin (9.8±1.4 vs. 11.9±0.8 g/dL, P<0.0001) and albumin (4.6±0.6 vs. 
4.8±0.2 g/dL, P=0.012). The CRP showed higher occurrence among patients (40% were positive for CRP). 
Calcium and phosphorus evaluation showed significantly lower calcium and higher phosphorus among patients. 
However, the difference in Ca X P product was not statistically significant. Conclusions: The study indicates 
that many of the CVD risk factors are associated with the different stages of CKD in children patients prior to 
dialysis, and that some of these factors are exacerbated as CKD progresses.
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INTRODUCTION
CKD disease is now being recognized as a major public 
health problem that is threatening to reach epidemic 
proportions over the next decade.[1] The annual incidence 
of end-stage renal disease (ESRD) in USA, UK and Europe 
is 33.6, 10, 13.5 per 100,000 population, respectively.[2]
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CKD is defined as kidney damage for ≥3 months, as 
confirmed by kidney biopsy or markers of kidney damage, 
with or without a decrease in glomerular filtration rate 
(GFR) or GFR <60 mL/min/1.73 m2 for ≥3 months, with 
or without kidney damage.[3]
Cardiovascular disease (CVD) remains the leading cause 
of morbidity and mortality in patients with ESRD, both in 
dialysis and in transplant patients.[4] Approximately, 50% of 
mortality in the dialysis population is due to CVD and the 
risk of death from CVD is elevated 30-fold for patients 
with ESRD as compared with the general population.[5] 
Cardiovascular morbidity and even mortality seems to be 
prevalent also among children and adolescents with ESRD, 
despite much lower exposure to “classical” risk factors for 
atherosclerosis, diabetes, smoking, and hyperlipidemia.[6]
There is accumulating evidence that the increase in CVD 
burden is present in patients prior to dialysis, due to both 
conventional risk factors as well as those specific to kidney 
disease.[4] Risk factors for the increased prevalence of CVD 
in CKD include traditional factors: Age, sex, diabetes, 
hypertension, smoking, obesity and those specific to CKD: 
Blood pressure changes, fluid imbalance, anemia, calcium/
phosphorus metabolism, malnutrition, hypoalbuminemia, 
hyperhomocysteinemia, inflammation, oxidant stress, 
insulin resistance, altered renin-angiotensin axis and 
endothelial dysfunction.[7]
Gaza strip constitutes part of the Palestinian territories, 
with an area of 365 Km², lying on the coast of the 
Mediterranean Sea. Gaza strip is a highly populated 
area with a total population of 1,600,000 inhabitants.  [8] 
Palestinian 2005 reports showed that the prevalence 
of renal failure was 4% with an incidence of 10.8 per 
100,000.[9]
This study was undertaken in order to investigate the 
association between various risk factors of CVD and 
different stages of CKD in children patients without kidney 
replacement therapy in Gaza strip.
MATERIALS AND METHODS
The present study is a cross-sectional study that was 
conducted from the beginning of December 2008 to 
the end of March 2009. The study was carried out at 
the Nephrology Department of Abd El-Aziz El-Rantisy 
Specialized Pediatric Hospital in Gaza strip, Palestine.
The study population consisted of 112 subjects; divided as 
60 CKD patients and 52 healthy control individuals. The 
control group was normotensive, non-diabetic children, 
with no history of renal or cardiovascular disease. Children 
in both control and patient groups were ≤12 and >1 years 
old. Regarding gender, males represented 40 (66.7%) of 
the patients and 28 (53.8%) of the controls, whereas 
females represented 20 (33.3%) of the patients and 24 
(46.2%) of the controls. The age of the study population 
was divided into three main age groups. The age group 
1–4 years represented 12 (20%) of the patients and 11 
(21.2%) of the controls. Twenty (33.3%) patients and 22 
(42.3%) controls belonged to the age group 5–8 years. 
Age group 9–12 years consisted of 28 (46.7%) patients 
and 19 (36.5%) controls.
Patients with kidney replacement therapy (hemodialysis, 
peritoneal dialysis or kidney transplantation), clinically overt 
inflammatory disease at the time of investigation, clinically 
significant overhydration or dehydration and those on anti-
lipid drugs were excluded from the study.
The study ethical considerations were fulfilled through 
coordination with the Palestinian Ministry of Health 
and the approval of Helsinki Committee. Moreover, 
parents of the participants were given full explanation 
about the purpose of the study and assurance about the 
confidentiality of the information collected, and their 
written consent was obtained.
The levels of creatinine, urea, albumin, cholesterol, 
triglycerides, high-density lipoprotein (HDL), low-
density lipoprotein (LDL), phosphorus, calcium, 
hemoglobin, glucose and C-reactive protein (CRP) 
were based on laboratory investigations of blood 
samples collected after 12–14 h overnight fasting. 
LDL in mg/dL was calculated by Friedewald equation:   
[cholesterol – (HDL + triglycerides/5)]. Spot urine samples 
were tested for albumin/creatinine ratio (ACR). The ACR 
was calculated as: ACR (mg/g) = microalbumin in urine 
(mg/L) x 1000/creatinine in urine (mg/dL) x10.
Glomerular filtration rate was estimated for all participating 
subjects according to the Schwartz formula: GFR (mL/
min/1.73m2) = 0.55 × length/serum creatinine. Height, 
weight and blood pressure were measured for each 
participant. Body mass index (BMI) was also calculated 
for all subjects. Face-to-face interview questionnaire was 
used to obtain information about history of the disease 
(for patients), history of CVD in the patients’ family and 
physical activity. According to the WHO, physical activity 
is defined as “any bodily movement produced by skeletal 
muscles that require energy expenditure,” In the current 
study, physical activity was measured as recommended Journal of Cardiovascular Disease Research Vol. 3 / No 2 93
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by the US Department of Health and Human Services 
(2008).[10]
Sampling and processing
Blood samples were collected from patients and controls 
who agreed to participate in the study after overnight 
12–14 h fasting. Five mL of blood was obtained from 
each subject and was divided into EDTA tube (1.0 mL) 
and plain tube (4.0 mL). A spot sample of morning urine 
in the fasting state was collected from each subject. Urine 
albumin, urine creatinine and CBC were done on the same 
day of collection. Serum samples were stored at -20ºC 
until the time of performing the analysis. All biochemical 
analyses were done in the laboratories of the Public Aid 
Hospital in Gaza.
Height, weight, BMI and blood pressure measurements
Height was measured to the nearest 1.0 cm and weight 
to the nearest 0.1 kg. BMI was calculated by dividing the 
weight in kilograms by the square of the height in meters. 
Blood pressure was measured in the right arm, with the 
subject in a relaxed, sitting position. The average of two 
measurements with a mercury sphygmomanometer was 
used for all subjects.
Biochemical analyses
Serum urea, creatinine, albumin, cholesterol, triglycerides, 
HDL, phosphorus, glucose, urine albumin, and urine 
creatinine were analyzed manually using Stat Fax-1904 
plus spectrophotometer (Awareness Technology Inc. 
Palm city- Florida-USA). Two levels of lyophilized multi-
control sera: Normal and abnormal levels were analyzed 
with each run. Serum total calcium was analyzed using 
ion-selective electrode by Nova 10 electrolyte analyzer 
(Nova Biomedical, Waltham city- Massachusetts-USA). 
Four levels of controls: I, II, III and IV, were analyzed 
with each run. CRP was analyzed using semi-quantitative 
latex method; positive and negative controls were used 
in each run. Complete blood count (CBC) was measured 
using Cell-DYN 1800 cell counter (Abbott, Wiesbaden city- 
Germany). Three controls (R and D systems, Minneapolis 
city- Minnesota- USA): High, normal and low, were used 
in each run of CBC.
Statistical analyses
Data entry and statistical analyses were performed using 
SPSS (Statistical Package for Social Sciences) software 
package version 11. The variables were analyzed using 
descriptive statistics and independent samples t-test. Results 
were expressed as frequency or mean±SD. The results were 
statistically significant when the P value was less than 0.05.
RESULTS
Measurements carried out for patients and controls 
are presented in Table 1. Significantly decreased height 
(104.7±21.2 vs. 121.3±20.0, P<0.0001) and weight 
(18.9±9.2 vs. 26.2±10.2, P<0.0001) were observed in 
the patients as compared with controls. In contrast, there 
was a significant increase in the systolic (111.4±18.5 
vs. 98.6±7.6, P<0.0001) and diastolic (70.3±17.6 vs. 
63.9±5.6, P=0.014) blood pressure in the patients as 
compared with the controls. Patients showed significantly 
higher levels of urea (130.0±62.0 vs. 22.0±8.0, P<0.0001) 
and creatinine (2.57±1.51 vs. 0.47±0.11, P<0.0001). 
Albumin/creatinine ratio also showed significantly higher 
values in the patients as compared with the controls 
(1792±3183 vs. 11.0±6.0, P<0.0001). The wide variation 
in ACR values between patients is the reason behind 
the observed large SD of the mean (SD=3183 mg/g), 
since the ACR values depend on the type of kidney 
disease. Regarding GFR, the results revealed that 
patients had significant reduction in GFR (30.9±18.4 
vs. 146.7±20.9, P<0.0001). As compared with the 
controls, the patients showed significantly higher levels 
of cholesterol (163.6±38.9 vs. 141.8±24.2, P=0.0001), 
triglycerides (145.5±67.1 vs. 82.9±35.7, P<0.0001) and 
LDL (92.6±31.9 vs. 72.5±19.0, P<0.0001). Meanwhile, 
the patients showed lower level of HDL (41.9±11.0 
vs. 52.7±11.7, P<0.0001). The results also indicated a 
significant difference between the patients and controls 








Height (cm)  104.7±21.2  121.3±20.0  <0.0001
Weight (kg)  18.9±9.2  26.2±10.2  <0.0001
SBP (mmHg)  111.4±18.5  98.6±7.6  <0.0001
DBP (mmHg)  70.3±17.6  63.9±5.6  0.014
Urea (mg/dL)  130.0±62.0  22.0±8.0  <0.0001
Creatinine (mg/dL)  2.57±1.51  0.47±0.11  <0.0001
ACR (mg/g)  1792±3183  11.0±6.0  <0.0001
GFR (ml/min/1.73m2)  30.9±18.4  146.7±20.9  <0.0001
Cholesterol (mg/dL)  163.6±38.9  141.8±24.2  0.0001
Triglycerides (mg/dL)  145.5±67.1  82.9±35.7  <0.0001
LDL (mg/dL)  92.6±31.9  72.5±19.0  <0.0001
HDL (mg/dL)  41.9±11.0  52.7±11.7  <0.0001
Hemoglobin (g/dL)  9.8±1.4  11.9±0.8  <0.0001
Albumin (g/dL)  4.6±0.6  4.8±0.2  0.012
Calcium (mg/dL)  9.2±1.4  10.3±0.4  <0.0001
Phosphorus (mg/dL)  5.7±1.3  5.2±0.5  0.006
Ca X P (mg2/dL2)  52.4±12.9  53.4±5.3  0.58294  Journal of Cardiovascular Disease Research Vol. 3 / No 2
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in terms of hemoglobin (9.8±1.4 vs. 11.9±0.8, P<0.0001) 
and albumin (4.6±0.6 vs. 4.8±0.2, P=0.012). The results 
revealed that patients had significantly lower calcium 
than controls (9.2±1.4 vs. 10.3±0.4, P<0.0001). In 
contrast, patients had significantly higher phosphorus as 
compared with controls (5.7±1.3 vs. 5.2±0.5, P=0.006). 
The difference in the Ca x P, however, was not significant.
CRP among patients and controls was measured by 
qualitative and semi-quantitative latex method. Table 2 
illustrates the frequency of positive and negative CRP in 
the subjects of the two groups.
Participants from both groups were investigated for 
some traditional CVD risk factors including diabetes, 
hypertension, physical inactivity, BMI, and family history 
of CVD. As shown in Table 3, no diabetic children were 
encountered in the study population. Hypertension was 
obvious in the patient group. Physical inactivity (PA) was 
higher in patients than control group. Physical activity 
is classified into two categories: “Inactive” refers to no 
PA beyond baseline activities of daily living or less than 
150 minutes/week of moderate-intensity PA and “Active” 
refers to ≥150 minutes/week of moderate/high-intensity 
activity.
Body mass index is divided into groups as recommended 
by the WHO: Underweight <18.5 kg/m2, Normal weight 
18.5–24.9 kg/m2, overweight 25–29.9 kg/m2, obesity 
≥30 kg/m2, morbid obesity >40.0 kg/m2.[11] Accordingly, 
the results showed that the majority of patients were 
underweight. The percentage of patients with family 
history of CVD was of nearly equal percentage of controls.
The patients were classified into 1 to 5 stages according 
to the National Kidney Foundation-Kidney Disease 
Outcomes Quality Initiative (NKF-KDOQI), New York- 
USA. NKF-KDOQI has provided evidence-based clinical 
practice guidelines for all stages of chronic kidney disease 
(CKD) and related complications since 1997. Twelve 
patients couldn’t collect urine because of difficulty in their 
urine voidance; the 12 cases belonged to Stage 4 and 5 of 
CKD. Four patients (in Stage 3) had normal ACR while 
other patients had abnormal ACR (albuminuria). Figure 1 
shows the percent distribution of the patients in each stage 
of CKD. The highest number of the patients belonged to 
Stage 4 followed by Stage 3, Stage 5, and then Stage 2. Stage 
1 was not encountered in the studied sample.
The values of cholesterol, triglycerides, HDL, and LDL at 
different stages of CKD in the patients are presented in 
Figure 2. Generally, the results showed a gradual increase 
in the levels of cholesterol (160.3±50.8, 166.9±48.6, 
155.2±28.8, and 186±25.7 mg/dL), triglycerides (117.7±8.0, 
120.3±64.5, 153.4±54.7, and 204±99.2 mg/dL), and LDL 
(96.7±40.8, 97.3±40.0, 83±22.3, and 109±22.6 mg/dL) in 
Stages 2, 3, 4 and 5, respectively. On the other hand, HDL 
generally showed a gradual decrease as CKD progressed 
(39.7±12.8, 45.6±7.5, 41.5±13.2, and 36.1±5.8 mg/dl) in 
Stages 2, 3, 4 and 5, respectively.
Figure 3 showed general decrease in hemoglobin (10.0±1.7, 
10.5±1.2, 9.4±1.3, and 9.2±1.8 g/dL), total serum calcium 
(9.6±1.1, 9.8±1.4, 8.8±1.2, and 8.3±1.2 mg/dL) in Stages 2, 
3, 4 and 5, respectively. The results of albumin (4.6 g/dL) 
were stable at different stages of CKD, while ACR fluctuated 
between stages (1657±3480, 951±2121, 2521±3090, and 
868± 209 mg/g in Stages 2, 3, 4 and 5, respectively). The 
results showed gradual increase of phosphorus (4.5±0.4, 
5.3±0.7, 6.0±1.4, and 7.2±1.2 mg/  dL) and Ca x P product 
(43.6±7.1, 52.6±12.8, 52.6±13.7, and 59.2±11.4 mg2/dL2) 
in Stages 2, 3, 4 and 5, respectively.
Distribution of CRP in the different stages of CKD is 








<6 mg/dL 36 (60.0) 49 (94.2)
Positive
6 mg/dL 3 (5.0) 3 (5.8)
12 mg/dL 13 (21.7) _
24 mg/dL 6 (10.0) _
48 mg/dL 2 (3.3) _
Table 3: Traditional cardiovascular (CVD) risk factors 




No. (%) No. (%)
Diabetes    
Yes 0 (0.0) 0 (0.0)
No 60 (100.) 52 (100)
Hypertension    
Yes 28 (47.0) 0 (0.0)
No 32 (53.0) 52 (100)
Physical inactivity    
Inactive 30 (50.0) 13 (25.0)
Active 30 (50.0) 39 (75.0)
BMI*  
Normal weight  10 (16.7) 13 (25.0)
Underweight 50 (83.3) 39 (75.0)
Family history of CVD    
Yes 22 (37.0) 20 (38.0)
No 38 (63.0) 32 (62.0)
*BMI: Body mass index. Normal weight=18.5–24.9 BMI (kg/m2). Underweight <18.5 
BMI (kg/m2)Journal of Cardiovascular Disease Research Vol. 3 / No 2 95
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Figure 1: Distribution of chronic kidney disease stages among patients
Figure 2: Relation between lipid profile and chronic kidney disease 
stages
Figure 3: Relation between hemoglobin, albumin, calcium, 
phosphorus, Ca x P, and albumin/creatinine ratio with stages of chronic 
kidney disease
Figure 4: C-reactive protein with respect to the chronic kidney disease 
stages
Figure 5: Distribution of some traditional cardiovascular disease risk 
factors with respect to chronic kidney disease stages
illustrated in Figure 4. The results showed that Stage 5 had 
the highest percentage of CRP-positive patients.
Figure 5 shows the frequency of some traditional CVD risk 
factors including hypertension, physical inactivity and BMI 
in various CKD stages. In general, there is a progressive 
increase in hypertension with CKD stages. Physical 
inactivity was also increased as CKD developed. Obesity, 
as a traditional risk factor, was not present since most of 
the patients were underweight; results showed there is a 
progressive weight loss with the development of CKD.
DISCUSSION
Patients enrolled in this study could be classified into four 
stages of CKD (Stage 2, 3, 4 and 5). Stage 4 presented with 
the highest incidence, followed by stage 3, then stage 5 and 
stage 2. The decreased presentation of Stage 5 in the study 
population is due to initiation of hemodialysis or peritoneal 
dialysis for many of Stage 5 patients and in some cases 
death of the patients before reaching Stage 5. Absence of 
Stage 1 and reduced number of Stage 2 patients in the study 
population is due to low number of patients in these stages 
referred and hospitalized in the Nephrology Department, 
because the disease in such early stage is asymptomatic and 
criteria of kidney impairment are very mild, especially in 
Stage 1. Unfortunately, no data regarding the prevalence of 
CKD stages is available in our population to compare the 
study findings with. This is due to underreporting of such 
diseases in Gaza strip. The National Health and Nutrition 
Examination Surveys in 1999–2004 in the USA estimated 
higher prevalence of Stage 3 followed by Stages 2 and 1, 
while Stage 4 represented the lowest prevalence, whereas 
Stage 5 was excluded.[12] The study of Annear et al. indicated 96  Journal of Cardiovascular Disease Research Vol. 3 / No 2
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that Stage 3 had higher prevalence followed by Stages 4 
and 5.[13] Essig et al. in their study on early CKD stages (1, 2 
and 3) found that Stage 3 had higher distribution followed 
by Stages 2 and 1.[14]
The study showed that the patients were shorter, had lower 
weight and had higher systolic and diastolic blood pressure. 
This result is congruent to the results of Litwin et al. who 
found that the patients were significantly smaller and lighter 
and had higher blood pressure than control subjects.[6] 
Other studies have indicated that CKD in growing children 
leads to a state of impaired growth due to altered metabolic 
status and defective growth hormone action,[15] and that 
high blood pressure is a leading cause of CKD in adults 
and contributes to the worsening of CKD in children.[16]
The present study showed that there is an association 
between hypertension and CKD. Forty-seven percent of 
patients had a history of hypertension and were treated 
with anti-hypertensive drugs. The relationship between 
hypertension and progression of CKD was clear within 
stages of CKD since the frequency of hypertensive 
patients gradually increased through Stages 2, 3 and 5. 
The results are in agreement with those of other authors 
who found an association between hypertension and CKD 
and showed that hypertension was frequent in all stages 
of CKD.[17-20] The link between CKD and hypertension 
is primarily through the renin-angiotensin system where, 
these hormones are released in response to chronic kidney 
damage and can contribute to a patient’s hypertension 
by stimulating both salt retention as well as constriction 
of blood vessels.[21] An analysis of blood pressure in the 
North American Pediatric Renal Transplant Cooperative 
Study (NAPRTICS) database estimated the prevalence of 
hypertension among children with CKD as being close to 
50% and demonstrated that renal function in hypertensive 
children with CKD deteriorated significantly more rapidly 
than in normotensive children, and raises the possibility 
that improved blood pressure control may be one method 
of slowing the progression of CKD in this population.[22] 
Another study that was carried out on CKD adult patients 
not receiving renal replacement therapy showed that 
76% of patients had history of hypertension.[23] Locatelli 
et al. found out that hypertension plays a major role in 
determining cardiac damage at all stages of CKD, including 
the dialytic phase.[24]
Half of the patients of the present study were physically 
inactive. With respect to CKD stages, the results showed 
that all cases in Stage 2 were active, inactivity was increased 
in Stages 3 and 4, and in Stage 5 all cases were inactive. This 
indicates a positive correlation between physical inactivity 
and CKD progression. Stein et al. reported in their study that 
physical inactivity was associated significantly with CKD.[25] 
Moreover, Shlipak et al. stated that low physical activity is a 
predictor of cardiovascular mortality in persons with CKD.[26]
In terms of BMI, the results showed that the frequency 
of underweight among patients was higher than controls. 
CKD stages in the study revealed that the frequency of 
underweight increased as GFR declined through Stages 2, 
4 and 5. Our results are in agreement with those Litwin 
et al.[6] Other studies, however, reported contradictory 
results, where they reported that obesity was a risk factor 
for CKD progression and that there was an increase in 
BMI as GFR declined.[27,28] Variation in the results may be 
because we studied the presence of obesity in our study 
population who are already suffering from CKD and not 
CKD as a sequel to obesity. Additionally, the prevalence 
of underweight in both the controls and patients may 
reflect the nutritional status or behavior of our children 
population.
In examining family history of CVD as a risk factor of 
CVD in the study population, the results indicated that 
there was no difference between patients and controls, 
since they had nearly equal percentages of subjects with 
family history of CVD. This observation confirms the 
involvement of genetic factor(s) in causing CVD.
In the general population, high plasma concentrations of 
LDL cholesterol, low concentrations of HDL cholesterol, 
and to some extent high total triglyceride concentrations are 
associated with increased atherosclerotic CVD risk.[29] There 
seems to be a gradual shift to the uremic lipid profile as 
kidney function deteriorates.[30] Uremic lipid profile shows 
dyslipidemia with elevated cholesterol and triglyceride 
and decreased HDL. Elevated plasma LDL cholesterol 
concentration is common in nephrotic syndrome but is 
not a typical feature of patients with advanced CKD.[31] 
Our study showed significant increase in total cholesterol, 
triglycerides and LDL in the patients as compared with the 
controls. The results also revealed significantly lower level 
of HDL in the patients. A gradual shift to the uremic lipid 
profile as CKD progresses was evident in the CKD stages 
of the present study. This finding is in agreement with 
other studies that assessed the association between CKD 
and some CVD risk factors including dyslipidemia.[18,20,23,24]
Elevation of albuminuria is associated with high risk of 
development of clinical nephropathy and CVD events.[32] 
More than one method can be used to determine urine 
albumin excretion.[33] In the present study, ACR in spot 
morning urine samples was used to measure albuminuria. Journal of Cardiovascular Disease Research Vol. 3 / No 2 97
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The results showed that there was association between 
CKD and increased level of ACR. Macroalbuminuria 
(ACR >300 mg/g) was predominant in the patients 
followed by microalbuminuria (ACR=30–300 mg/g), 
while few patients (8.3%) had normal albuminuria (ACR 
<30 mg/g). Albuminuria showed irregularity between 
stages of CKD, i.e., ACR levels fluctuated between stages. 
This irregularity can be attributed to the cause of the 
renal disease, since albuminuria varies according to the 
cause of the renal disease.[34] Our findings are congruent 
with other studies, which suggested that albuminuria is a 
common feature in CKD and is related to the underlying 
glomerular or interstitial damage.[7,18] Several investigators 
have shown that there is a continuous association between 
the level of albuminuria and the risk for CVD, and thus, 
macroalbuminuria or clinical proteinuria is associated 
with a higher risk for CV morbidity and mortality than 
microalbuminuria. The presence of macroalbuminuria is a 
clear manifestation of overt nephropathy and is associated 
with faster deterioration of kidney function.[35-37]
Anemia has been shown to be significantly associated with 
left ventricular hypertrophy (LVH) in both dialysis patients 
and patients with early CKD, suggesting that anemia 
is primarily implicated in the development of LVH in 
CKD.  [38,39] Anemia is a potentially modifiable risk factor; its 
treatment seems to have a more beneficial effect on LVH 
regression if it is given as early as possible during the course 
of CKD and before patients have reached ESRD.[24] In the 
present study, the majority of patients were anemic and the 
results showed a continuous decrease of hemoglobin in 
Stages 3, 4 and 5, which indicates an association between 
anemia and CKD progression in the study population. 
These results are congruent with that of other authors who 
found an association between CKD and low hemoglobin 
or hematocrit in predialysis CKD patients.  [23,24] Goicoechea 
et al. in their study on CKD patients, and after a mean 
follow-up of 22.3 months, found that some of the patients 
had a cardiovascular event; the patients who suffered from 
cardiovascular event were older, more anemic, and had 
higher pulse pressure.[17]
With respect to stages of CKD, the results showed a 
gradual decrease in total calcium and a progressive rise 
in phosphorus levels as CKD progresses. The levels of   
Ca x P product also showed continuous increase in 
Stages 2, 3, 4 and 5. This finding of calcium–phosphorus 
metabolism indicates the association of progressive 
nephron loss with phosphorus retention and hypocalcemia 
in pre-dialysis patients.
Hypercalcemia can develop when patients (mainly in 
late stages of CKD and dialysis) are given calcium 
and/or vitamin D and due to increased levels of 
parathyroid hormone (PTH), which increases calcium and 
phosphorus ion product. Hyperparathyroidism along with 
hyperphosphatemia and increased calcium phosphate ion 
product are identified as independent CVD risk factors.  [40] 
The results of the present study are in accordance with 
Zehnder et al. study, which showed that serum phosphorus 
and PTH concentrations were elevated among patients and 
indicated that calcium–phosphate disorders were important 
CVD risk factors in CKD.[41]
Regarding CRP, the results showed that patients had higher 
percentages of positive CRP (CRP>6 mg/L) than controls. 
Stage 5 had the highest percentages of CRP-positive 
patients with percentages decreasing through Stage 2, 
stage 3 and then stage 4. The rise in inflammatory state of 
CKD (especially in stage 5) may be due to an increase of 
uremia (which is a state of chronic inflammation), reduced 
renal clearance of cytokines, and accumulation of advanced 
glycation end products.[42,43] Inflammation and increased 
level of CRP in patients with CKD was also observed in 
other studies, which reported that patients with CKD had 
elevated levels of CRP.[20,23]
There is a growing evidence that inflammation probably 
plays a key role in the initiation and progression of the 
atherosclerotic process.[44] High serum concentrations of 
markers of systemic inflammation (including C-reactive 
protein and interleukin-6) have been associated with 
atherosclerosis.[42,43]
In conclusion the present study showed a significant 
association between a number of CVD risk factors 
and CKD stages prior dialysis. These factors included 
hypertension, dyslipidemia, physical inactivity, anemia, 
albuminuria, hypoalbuminemia, and inflammation.
Identification of those risk factors among patients with 
CKD is potentially useful for raising awareness of the 
relationship between CKD and CVD, and should encourage 
clinicians to evaluate their CKD patients for those factors 
which are useful in monitoring the progression of the 
disease and predicting the future outcomes. Moreover, 
amelioration and treatment of CV risk factors at earlier 
stages of CKD may be effective in reducing CVD events 
both before and after the onset of kidney failure.
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